Online inquiry

IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9954MR)

This product GTTS-WQ9954MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets hly gene. The antibody can be applied in Staphylococcal infections research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2828033
UniProt ID P09616
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9954MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2644MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 592
GTTS-WQ15757MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA WX-G250
GTTS-WQ3063MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ4072MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI 836
GTTS-WQ14634MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ4890MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BYM338
GTTS-WQ7906MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GSK-249320
GTTS-WQ5202MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CAT-8015
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW